RT Journal Article
SR Electronic
T1 Night work and prostate cancer risk: results from the EPICAP Study
JF Occupational and Environmental Medicine
JO Occup Environ Med
FD BMJ Publishing Group Ltd
SP 573
OP 581
DO 10.1136/oemed-2018-105009
VO 75
IS 8
A1 Méyomo Gaelle Wendeu-Foyet
A1 Virginie Bayon
A1 Sylvie Cénée
A1 Brigitte Trétarre
A1 Xavier Rébillard
A1 Géraldine Cancel-Tassin
A1 Olivier Cussenot
A1 Pierre-Jean Lamy
A1 Brice Faraut
A1 Soumaya Ben Khedher
A1 Damien Léger
A1 Florence Menegaux
YR 2018
UL http://oem.bmj.com/content/75/8/573.abstract
AB Objective To investigate the role of night work in prostate cancer based on data from the EPICAP Study.Methods EPICAP is a French population-based case-control study including 818 incident prostate cancer cases and 875 frequency-matched controls that have been interviewed face to face on several potential risk factors including lifetime occupational history. Detailed information on work schedules for each job (permanent or rotating night work, duration, total number of nights, length of the shift, number of consecutive nights) as well as sleep duration and chronotype, was gathered. Prostate cancer aggressiveness was assessed by Gleason Score.Results Night work was not associated with prostate cancer, whatever the aggressiveness of prostate cancer, while we observed an overall increased risk among men with an evening chronotype (OR=1.83, 95% CI 1.05 to 3.19). A long duration of at least 20 years of permanent night work was associated with aggressive prostate cancer (OR=1.76, 95% CI 1.13 to 2.75), even more pronounced in combination with a shift length >10 hours or ≥ 6 consecutive nights (OR=4.64, 95% CI 1.78 to 12.13; OR=2.43, 95% CI 1.32 to 4.47, respectively).Conclusion Overall, ever night work, either permanent or rotating, was not associated to prostate cancer. Nevertheless, our results suggest that a long duration of permanent night work in combination with a long shift length or at least six consecutive nights may be associated with prostate cancer, particularly with aggressive prostate cancer. Further studies are needed to confirm those findings.